Related Experiment Video
Updated: Apr 19, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Prenatal exposure to polybrominated diphenyl ethers and polyfluoroalkyl chemicals and infant neurobehavior
Stephanie Donauer1, Aimin Chen2, Yingying Xu1
1Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Insights
Prenatal exposure to perfluorooctanoic acid (PFOA) was linked to increased odds of infant hypotonia. Polychlorinated biphenyl ethers (PBDEs) showed no association with infant neurobehavioral outcomes.
Area of Science:
- Environmental Health
- Neuroscience
- Pediatrics
Background:
- Prenatal exposure to environmental chemicals like polybrominated diphenyl ethers (PBDEs) and polyfluoroalkyl chemicals (PFCs) may impact infant neurodevelopment.
- Understanding these associations is crucial for public health and early intervention strategies.
Purpose of the Study:
- To investigate the relationship between prenatal exposure to PBDEs and PFCs and early infant neurobehavioral outcomes.
- To assess the impact of specific chemicals, including BDE-47, perfluorooctanoic acid (PFOA), and perfluorooctane sulfonic acid (PFOS), on infant neurobehavior.
Main Methods:
- A cohort study of 349 mother/infant pairs was conducted.
- Maternal serum concentrations of PBDEs and PFCs were measured during pregnancy.
- Infant neurobehavior was assessed at 5 weeks using the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS).
Main Results:
- No significant associations were found between overall PBDE or PFC exposure and individual NNNS outcomes.
- Latent profile analysis identified neurobehavioral profiles: social/easygoing, high arousal/difficult, and hypotonic.
- A 10-fold increase in prenatal PFOA was associated with a significantly higher likelihood of being categorized as hypotonic (aOR 3.79).
Conclusions:
- Higher prenatal perfluorooctanoic acid (PFOA) concentrations are associated with an increased risk of infant hypotonia.
- No association was found between prenatal polybrominated diphenyl ether (PBDE) exposure and hypotonia.
- Further research is recommended to explore the link between prenatal PFC exposure and infant muscle tone.
Objective:
To assess the impact of prenatal exposure to polybrominated diphenyl ethers (PBDEs) and polyfluoroalkyl chemicals (PFCs) on early infant neurobehavior.
Study Design:
In a cohort of 349 mother/infant pairs, we measured maternal serum concentrations during pregnancy of PBDEs, including BDE-47 and other related congeners, as well as 2 common PFCs, perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid. When the infants were 5 weeks of age, we measured their neurobehavior by using the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS).
Results:
Neither PBDE nor PFC exposures during gestation were associated with the 11 individual NNNS outcomes included in our study; however, when we used latent profile analysis to categorize infants into neurobehavioral profiles based on performance on the NNNS (social/easygoing, high arousal/difficult, or hypotonic), a 10-fold increase in prenatal PFOA concentrations significantly increased the odds of being categorized as hypotonic compared with social/easygoing (aOR 3.79; 95% CI 1.1-12.8).
Conclusions:
Infants of mothers with greater serum concentrations of PFOA during pregnancy were more likely to be categorized as hypotonic. No association between PBDE concentrations and hypotonia was found. Additional studies should further investigate possible associations of prenatal PFC exposure and muscle tone in infants and children.
More Related Videos
07:08Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
Published on: March 6, 2018
08:28Assessment of the Effects of Endocrine Disrupting Compounds on the Development of Vertebrate Neural Network Function Using Multi-electrode Arrays
Published on: April 26, 2018
Related Concept Videos
Teratogenicity
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....